VRDN

Viridian Therapeutics, Inc. (VRDN) - 10-Q Summary for Period Ended June 30, 2026

Business Context and Reporting Period

This Quarterly Report covers the period ended June 30, 2026. Viridian Therapeutics is a biopharmaceutical company focused on autoimmune and rare diseases. The reporting period marks a significant transition as the company received FDA approval for its lead product, veligrotug (Lumvoa), for the treatment of Thyroid Eye Disease (TED) in June 2026. The company has established commercial infrastructure to support the U.S. launch of veligrotug and continues to advance its pipeline, including the subcutaneous candidate elegrobart and FcRn inhibitors.

Key Financial Metrics

Note: The company has not generated revenue from product sales prior to the June 2026 approval of veligrotug. Reported revenue consists of license and collaboration fees.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased to $0.4 million from $0.1 million, driven by license revenue from the Kissei Pharmaceutical agreement and collaboration revenue from Zenas BioPharma/Zai Lab.
• Expense Increases: SG&A expenses surged by $56.3 million (151% increase) year-over-year, primarily due to increased headcount and professional fees to support the commercial launch of veligrotug. R&D expenses decreased by $14.3 million, largely due to the timing of clinical trial costs for the TED portfolio.
• Debt Restructuring: The company issued $250.0 million in 1.75% Convertible Senior Notes due 2032 in May 2026. Proceeds were used to fully prepay and terminate the Hercules Loan and Security Agreement, resulting in a $4.1 million loss on extinguishment of debt.
• Liability Changes: The liability related to the sale of future revenue (DRI agreement) increased to $113.6 million following the achievement of a $75.0 million milestone payment upon FDA approval of veligrotug.

Guidance, Outlook, and Risks

• Commercial Launch: Viridian has launched veligrotug in the U.S. and is focused on market access, payer engagement, and physician education. The company expects to submit a Biologics License Application (BLA) for elegrobart in Q1 2027.
• Liquidity: With $981.5 million in cash and marketable securities, management expects to fund operations for at least 12 months. The company anticipates continued significant losses as it builds commercial capabilities.
• Key Risks:
  • Regulatory & Clinical: Risks associated with the approval of elegrobart and other pipeline candidates, including potential delays or failure to meet endpoints.
  • Manufacturing & Supply Chain: Reliance on third-party manufacturers, including WuXi Biologics in China, exposes the company to geopolitical risks and potential supply disruptions (e.g., BIOSECURE Act implications).
  • Commercialization: Uncertainty regarding market adoption, pricing, and reimbursement for veligrotug in a competitive landscape (e.g., Tepezza).
  • Capital Requirements: Continued need for significant capital to fund operations and commercialization; failure to raise additional capital could force program delays.

Investor Verification Checklist

• Commercial Execution: Verify early sales data and market uptake of veligrotug (Lumvoa) post-launch.
• Elegrobart Timeline: Confirm the status of the REVEAL-1 and REVEAL-2 trials and the projected Q1 2027 BLA submission date.
• Manufacturing Resilience: Assess the company's contingency plans regarding reliance on Chinese CDMOs (WuXi) amidst U.S. regulatory scrutiny (BIOSECURE Act).
• Cash Burn Rate: Monitor the rate of cash consumption as SG&A expenses remain elevated for commercial build-out.
• DRI Agreement Milestones: Track the achievement of remaining milestones under the DRI Healthcare Acquisitions LP agreement to unlock further funding.